arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Digital Health Summit USA 2016

Accelerating Patient Empowerment in Health and Wellness

New York |
Speakers include:
Amrit Ray

Amrit Ray

Janssen Pharmaceuticals

Esther Dyson

Esther Dyson

Executive Founder of Way to Wellville

Bakul Patel

Bakul Patel

US Food and Drug Administration (FDA)


With the healthcare industry continuing to experience an explosion of innovative technologies, regulatory bodies and associations are going to have a greater role to play in the speed in which digital health is truly realized. Combined with patient representatives having greater input into the formats and delivery of healthcare, the industry is still at a crucial turning point as wider market acceptance and international opportunities for digital devices hang in the balance.

Following the success of the inaugural FT Digital Health Summit USA, the event returns this year to once again target the most pressing challenges and opportunities within the industry. Expanding the expert speaker roster to include greater patient representation, the agenda will look at how the wider consumer market is accepting digital health technologies as well as their potential in driving more proactive healthcare.

fallback Add to my Calendar 10/27/2016 08:00:0010/27/2016 17:10:00trueFT Digital Health Summit USA 2016With the healthcare industry continuing to experience an explosion of innovative technologies, regulatory bodies and associations are going to have a greater role to play in the speed in which digital health is truly realized. Combined with patient representatives having greater input into the formats and delivery of healthcare, the industry is still at a crucial turning point as wider market acceptance and international opportunities for digital devices hang in the balance.Following the success of the inaugural FT Digital Health Summit USA, the event returns this year to once again target the most pressing challenges and opportunities within the industry. Expanding the expert speaker roster to include greater patient representation, the agenda will look at how the wider consumer market is accepting digital health technologies as well as their potential in driving more proactive healthcare.FT-Digital-Health-Summit-USA-20161b75c335be5b98390f78199b8bb549cbMM/DD/YYYY

Untitled Block

"Excellent conference, great speakers, kept dialogue at a higher strategic level the whole time. Exceeded my expectations."
RJ Lewis, Founder and CEO, eHealthcare

"A great forum to help calibrate where the digital/virtual healthcare is and where it's going."
Marc Salois, RVP Sales, Omada Health


Digital Health Summit USA Brochure

Digital Health USA 2016 Brochure

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

For more information about how we use your data please refer to our privacy and cookie policies.

Invites and offers from the FT

Receive exclusive personalised events invitations, carefully-curated offers, future speaking engagements and promotions from Financial Times Live

Thank you for submitting your details. Please download the event brochure.

Speaker Presentations

Speaker presentations:

André Larente, President, DIAGNOS - click here

Artem Petakov, President and Co-founder, Noom - click here

Jean Nehme, CEO, Touch Surgery - click here

Ryan Olohan, Head of Healthcare, Google - click here

Yitzhak Peterburg, Chairman of the Board of Directors, Teva Pharmaceutical Industries - click here


FT Digital Health Summit US - Photographs

To view the full selection of photographs from the FT Digital Health Summit US 2016 please click here.


Speakers (28)

Amrit Ray

Amrit Ray

Chief Medical Officer
Janssen Pharmaceuticals

Amrit Ray serves as Chief Medical Officer & Head of the Global Medical Organization for Johnson & Johnson's pharmaceuticals group, Janssen. Dr Ray advocates for patients across the organization and promotes ethical, evidence-based, and patient-centric decision-making. Johnson & Johnson, the world’s most comprehensive and broadly based manufacturer of health care products, has approximately 127,000 employees that work to touch the lives of over a billion people daily.

As Chief Medical Officer, Dr Ray has global responsibility for ensuring the safe, effective and appropriate use of Johnson & Johnson’s 1,000+ pharmaceutical products, and for supporting an innovative research pipeline of new medicines. He Chairs the senior governance body for decision-making on Patient Safety, and Chairs the J&J Bioethics committee. He leads groups responsible for the independent medical assessment of benefits and risks for all drugs, biologics and vaccines, from first human exposure through clinical trials, and all market activity.

Dr Ray is part of the R&D leadership team for Janssen’s research programs across Oncology, Immunology, Cardiovascular, Infectious Diseases, and Neuroscience, and leads centers of special patient focus such as Compassionate Access. By background, he is a physician scientist with global experience in medical research. He joined J&J in 2009 to serve as Chief Safety Officer, and was appointed Chief Medical Officer in 2012. Previously, he served in positions of increasing responsibility in Clinical Development, Medical Affairs, and Safety & Epidemiology at Pfizer and at Bristol-Myers Squibb. Dr Ray earned Immunology and Medical degrees from Edinburgh University Medical School.

Following bench research experience at Sir Joseph Lister Labs and early clinical training at Edinburgh Royal Infirmary, he began his career serving as a hospital doctor delivering patient care in the British National Health Service. He began his clinical research interests in obesity at the Mayo Clinic. Dr Ray also earned an MBA from Dartmouth’s Tuck School of Business and built business experience as a McKinsey analyst focusing on corporate finance and M&A. Dr Ray has been awarded distinctions for the development of new medicines in Women’s Health, Immunology and Cardiovascular, and his contributions have been recognized by the U.S. Congress, patient advocates, and public health groups. He has authored numerous scientific papers and has been invited to provide testimony and expert input to the World Health Organization, U.S. Congress, USAID, Brookings Institution, Bill & Melinda Gates Foundation, Institute of Medicine, UK MHRA and NICE, Chinese FDA, and other international forums on how medicines can create value and have a positive impact in the lives of patients.

Esther Dyson

Esther Dyson

Chairman of EDventure
Executive Founder of Way to Wellville

Esther Dyson is Chairman of EDventure Holdings and Founder of, for Health Initiative Coordinating Council.  HICCup is an open-source, evidence-generating project devoted to defining and testing a business model for producing community health (not health care) that will return profits to investors and health to the participants. It will use a contest in order to entice the best communities to compete and to give their successes and (educational) failures visibility. Its slogan: "Five places, five metrics, five years!"  In addition, Ms Dyson spends her time investing in and nurturing start-ups, with a recent focus on health care and aerospace.  From October 2008 to March of 2009, she lived in Star City outside Moscow, Russia, training as a backup cosmonaut.  On the health side, she is an investor in 23andMe (also a Director), Applied Proteomics, Crohnology, Eligible API,  Genomera, GeriJoy,  GreenGoose (closed), Health Loop, HealthRally, HealthTap, i2Dx, Keas (also an Advisor), Medivo, mEquilibrium, Omada Health, Organized Wisdom, PatientsLikeMe, PatientsKnowBest (UK), Resilient, Sleepio (UK), StartupHealth, Tocagen, Valkee (Finland), VitaPortal (Russia, also an Advisor) and Voxiva (also a Director).  She recently served on the selection panel for the Robert Wood Johnson Foundation Young Leader Awards and is active on the "health not healthcare" speaker circuit.  More generally, she is an active board member for a variety of startups, including also Airship Ventures, Eventful, Luxoft, Meetup, NewspaperDirect,  PA Consulting, WPP Group (not a start-up!), XCOR Aerospace and Yandex (recent IPO).  Her past investments have included Medstory (sold to Microsoft), Flickr and (sold to Yahoo!), Brightmail (sold to Symantec) and Vizu (recently sold to Nielsen).   Her current investments include AdKeeper, Amicus, AnchorFree, ChallengePost,  Cognitive Match (UK), Crowdbooster, Factual, Flattr (Sweden), GoodData, GridPoint, Ji Grahak (India),, LinkedIn, Linqia, Payperks,  PlanGo (Finland), School of Everything (UK), Skygrid, Square, SocialBon, Sparked, ThingD, Trusted ID,  txteagle/Jana, Vizu;  AlterGeo, Ostrovok TerraLink and  Zingaya in Russia; and  Icon Aircraft (light sport aircraft), Nanoracks and  Space Adventures (which organizes programs for space tourists) in the aerospace sector.  Ms Dyson also sits on the boards of several nonprofits, including  the the Eurasia Foundation, the Sunlight Foundation, the Personal Genome Foundation, the Commercial Spaceflight Federation and She has a BA in Economics from Harvard and was Founding Chairman of ICANN from 1998 to 2000. In addition, she wrote the best-selling, widely translated book Release 2.0: A design for living in the digital age,  published by Broadway Books, in 1997.  She writes a monthly column for 

Bakul Patel

Bakul Patel

Associate Director for Digital Health
US Food and Drug Administration (FDA)

Bakul Patel is Associate Director for Digital Health, at the Center for Devices and Radiological Health (CDRH), at the Food and Drug Administration (FDA).  Mr Patel leads regulatory policy and scientific efforts at the Center in areas related to emerging and converging areas of medical devices, wireless and information technology. This includes responsibilities for mobile health, health information technology, cyber security, medical device interoperability, and medical device software.  

Mr Patel is the FDA liaison between the Federal Communications Commission (FCC) and the Office of the National Coordinator (ONC). Since its inception in 2013, he chairs the International Medical Device Regulators Forum (IMDRF) “software as a medical device” working group, a global harmonization effort.

Before joining FDA, Mr Patel held key leadership positions working in the telecommunications industry, semiconductor capital equipment industry, wireless industry and information technology industry. Mr Patel’s experience includes Lean Six Sigma, creating long and short-term strategy, influencing organizational change, modernizing government systems, and delivering high technology products and services in fast-paced, technology-intensive organizations.

Mr Patel earned an MS in Electronic Systems Engineering from the University of Regina, Canada, and an MBA in International Business from The Johns Hopkins University.

Yitzhak Peterburg

Yitzhak Peterburg

Chairman of the Board of Directors
Teva Pharmaceutical Industries

Yitzhak Peterburg was appointed Teva’s Chairman on the Board of Directors on January 1, 2015, after re-joining Teva’s Board of Directors in 2012. Prior to this appointment he held the position of Teva’s Group Vice President for Global Branded Products (2010-2011), after serving on Teva’s Board of Directors from 2009 until July 2010.

Previously, he was a Professor in the School of Business Administration at Ben-Gurion University, Beer-Sheba, and a board member of the Israel National Institute of Health Policy and Health Services Research. Following this, Professor Peterburg was CEO and President of Cellcom, a leading Israeli cellular company (2003 – 2005), and the director general of Clalit Health Services, a leading health-care provider in Israel that is considered to be the second-largest HMO in the world. In this role he led the digitizing of Clalit services.

Professor Peterburg received his doctorate in public health from Columbia University. His earlier education includes a medical degree from Hadassah Medical School at Hebrew University of Jerusalem and a masters degree in information systems from the London School of Economics.

Jody Holtzman

Jody Holtzman

Senior Vice President, Market Innovation

Jody Holtzman has over twenty-five years of experience helping companies develop and implement competitive strategies and achieve their strategic market goals, Jody now leads the Market Innovation group for AARP, where he brings a non-traditional perspective to the field of aging shaped by a 20-year career in strategy, innovation, and organizational change.

At AARP, Jody is focused on ways to spark innovation in the market to benefit people over 50. In this role he envisioned and developed the concept of the $7.6 trillion Longevity Economy; co-founded and launched the Longevity Network,, with United Healthcare; and, created the Innovation@50+ LivePitch franchise which has attracted over 1,000 applicants and seen 27 out of the first 50 finalists raise over $175 million in venture investment.

Jody’s work has been published in Venture Capital Review, the Journal of Business Strategy, Competitive Intelligence Magazine, the Competitive Intelligence Anthology, and Making Cents Out of Knowledge Management. He has a graduate degree in international political economy from the University of Chicago.

Ryan Olohan

Ryan Olohan

National Industry Director, Healthcare

As the National Industry Director for Healthcare at Google, Ryan Olohan leads the teams responsible for developing and managing Google's relationships with pharmaceutical and consumer health companies. Mr Olohan and his teams partner with the largest companies in the world to leverage Google's search, display, mobile, online video, and other platforms. His teams are also responsible for connecting the vast health resources and innovation at Google in an effort to push the industry forward. His relentless push is why he was selected by MM&M as a “Top 40 Healthcare Transformer of 2016”.

Before Healthcare, he spent the majority of his 10 years at Google overseeing the CPG industry as the Head of Consumer Packaged Goods. Prior to Google, he was a consultant for Hewitt Associates and a Vice President of Implementations at Bank of NY Mellon before getting the itch to lead Business Development at two prominent startups. Outside of his day job, he is a frequent speaker at industry events and is a Board member for the Chopra Foundation, the Consumer Healthcare Products Association, and the Digital Health Coalition. He is also the founder of the Google Healthcare Advisory Board and the co-author of the widely acclaimed "Pharma 3D" ( in partnership with Google, McKinsey, and Wharton.

Tom Beauregard

Tom Beauregard

Executive Vice President and Chief Innovation Officer
UnitedHealth Group

Tom Beauregard is Executive Vice President and Chief Innovation Officer of UnitedHealth Group. As a member of the core leadership team, he identifies strategies to extend sustainable coverage for all Americans and leads the Enterprise Research and Development team that develops and launches meaningful innovations. He is a noted health care industry expert with broad strategy and implementation experience. Recent innovation accomplishments include a National Diabetes Prevention Program in partnership with the Y-USA and the Centers for Disease Control and Prevention, an evidence-based childhood obesity solution, and a reality TV-based diabetes prevention program (Project NOT ME) that earned him a regional Emmy for his role as an Executive Producer.

Mr Beauregard previously served as the CEO of a UnitedHealthcare business (United Essentials), where he was responsible for research and new product development. In this role his team conducted extensive employer and consumer research and developed related programs and products that extended appealing and affordable coverage to targeted employer and consumer segments. Mr Beauregard’s team has launched several highly innovative solutions that include new breakthroughs in affordable coverage solutions, advanced consumer choice models, value based incentive models, and portable insurance solutions. Prior to joining UnitedHealth Group, he was the National Practice Leader for Hewitt Associates, a global management consulting firm.

Mr Beauregard has over 25 years of healthcare leadership experience and is one of the industry’s leading experts on the forefront of dramatic change. He is a graduate of Hobart College’s economics program and earned an MBA from the University of Connecticut.

Susan Shiff

Susan Shiff

Senior Vice President, Center for Observational and Real-World Evidence

Susan Shiff joined Merck in 2014 as Senior Vice President and head of the CORE organization. CORE links together epidemiologists, health economists, access and reimbursement scientists, health services researchers and others involved in health policy research with the goal of leading global strategic value evidence generation and access strategy development to optimize reimbursement and patient outcomes across Merck’s portfolio.

Prior to joining Merck, Dr Shiff was the Global Vice President, Health Economics Research and Evidence Based Medicine at Teva. Prior to Teva, she spent seven years at Pfizer, including several years as Vice President in the areas of outcomes research, epidemiology, health economics, and access and pricing. She has also led the global risk management group and US HEOR group at Roche and spent four years at the US Centers for Disease Control and Prevention (CDC).

Dr Shiff received her PhD degree from UCLA, and an MBA degree from Cornell University. She currently serves on the Institute for Clinical and Economic Review (ICER), Advisory Board and Methods Sub-Committee; Health Technology Assessment International (HTAi), Policy Advisory Board; the Innovation and Value Initiative (IVI), Panel of Health Advisors, the Academy of Managed Care Pharmacy (AMCP) Foundation Board, and the New Jersey Symphony Orchestra, Board of Trustees, Education, and Development Committees. She is also a Non-Executive Director of Synthace Ltd. In 2016, Dr Shiff was named one of the top 15 women in Biopharma by FiercePharma.

Artem Petakov

Artem Petakov

President and Co-founder

A programmer from the age of nine, Artem Petakov has long believed in the power of technology to help people adopt healthier habits. He holds a BS in Computer Science from Princeton University, was a Robocup World Champion, and formerly worked at Google.

Jean Nehme

Jean Nehme

Touch Surgery

Jean Nehme trained as a plastic surgeon at Imperial College London, where he co-founded Touch Surgery with Dr Andre Chow. Dr Nehme has multiple awards for his research in innovation and application of surgical technology and simulation. He is passionate about the future of healthcare with the inclusion of technologies such as AI and Robotics. He has presented at multiple international conferences and won the Founders Forum Singapore Rising Star award and the London Business School Deloitte Digital Health Award in 2015.

Touch Surgery is a mobile platform for surgical training.  This simulation combines PixarTM quality animation process with game development to cognitively map surgical and interventional procedures into a virtual reality simulation. The Touch Surgery app connects more than 850.000 users in the Global Surgical Community to enable better decision making in the operating room. The data collected by Touch Surgery can be used to evaluate levels of knowledge and competencies gained.

At this time when the healthcare industry is facing multiple challenges globally, Dr Nehme strongly believes the solutions lie in leveraging on technological advancements. A mobile and connected surgical audience is the first step to transforming surgery worldwide.

Judy Sewards

Judy Sewards

Vice President, Head of Digital Strategy & Data Innovation

Judy Sewards serves as Vice President, Head of Digital Strategy & Data Innovation at Pfizer, where she is responsible for accelerating the adoption of robust digital and data solutions and compliant policies across the enterprise.  In this role, she leads a team focused on bringing to market those future strategies that will have the greatest impact in connecting with customers and meeting business needs in a rapidly changing health landscape.

In her tenure at Pfizer, Ms Sewards has held various leadership positions across the organization including team leader for the U.S. Celebrex and Flector Patch businesses, head of the Primary Care U.S. Marketing Innovation Incubator and consumer lead for the iconic Viagra brand.

Prior to Pfizer, Ms Sewards led client insights, brand strategy and advertising for the Merrill Lynch Global Wealth Management brand. In addition, she brings diverse experience ranging from tech start up to brand planning and management consulting. She received her BA degree from Smith College, where she also served as a member of the Board of Trustees.

Steven Corwin

Steven Corwin

President and CEO

Steven Corwin is President and Chief Executive Officer of NewYork-Presbyterian, one of the nation’s largest and most comprehensive healthcare delivery networks. Under Dr Corwin’s leadership, NewYork-Presbyterian has nearly doubled in size, providing world-class care to more than 2 million patients per year. Distinguished by its academic partners—Weill Cornell Medicine and Columbia University College of Physicians and Surgeons—NewYork-Presbyterian pursues clinical excellence, engages in pioneering medical research and provides outstanding medical education to the next generation of doctors. For more than a decade, NewYork-Presbyterian is consistently the top-ranked hospital in New York on U.S. News & World Report’s annual survey of “Best Hospitals,” as well as among the top 10 hospitals nationwide.

After having been instrumental in one of the more successful full-asset mergers in the health provider space (NY Hospital and Presbyterian Hospital), one of Dr Corwin’s core focuses as CEO has been on introducing innovative approaches to patient-centered care – with a keen eye on creating new pathways around access to care. Most notably, he led the way in establishing a regional care ecosystem via the NewYork-Presbyterian Regional Hospital Network and NewYork-Presbyterian Medical Groups, which enable patients to receive NewYork-Presbyterian’s world-renowned care directly in their own communities. Dr Corwin also has been a champion for numerous patient-centric technological initiatives, including on-demand access to electronic medical records, telehealth programs and digital health incubation.

Prior to his appointment as CEO, he served as Chief Medical Officer and later Chief Operating Officer. In these roles he led the development and implementation of 13 clinical service lines, a critical step for the success of the newly merged Hospital, and would advance key initiatives around quality and patient safety as well as clinical and technological innovation. Dr Corwin also helped build physician and institutional relationships for the newly merged health system, expand the focus on providing care to underserved communities, and maintain the Hospital’s financial and operational strength. He began his career as a cardiologist and internist at the hospital in 1979.

Dr Corwin serves as President of the Board of Directors of the Greater New York Hospital Association.

Deborah Kilpatrick

Deborah Kilpatrick

Evidation Health

Deborah Kilpatrick is the CEO of Evidation Health, a digital health company headquartered in San Mateo, CA. Evidation applies machine learning and predictive analytics to medical and behavioral data from connected populations to quantify outcomes in the digital era of medicine. Prior to her role at Evidation Health, Dr Kilpatrick was the Chief Commercial Officer of genomic diagnostics company CardioDx, whose Corus CAD product was named in the Wall Street Journal Technology Innovation Awards, TIME Magazine's Top 10 Medical Breakthroughs, and the Edison Awards. Earlier in her career, she held multiple leadership roles at Guidant Corporation, including Research Fellow, Director of R&D, and Director of New Ventures in the Vascular Intervention Division.  

Dr Kilpatrick serves on the Georgia Tech Advisory Board, chairs the Georgia Tech College of Engineering Advisory Board, and is a Fellow of the American Institute of Medical and Biological Engineering. She is a co-founder of the MedtechVision Conference now held annually in Silicon Valley, and she has been named to FierceBiotech’s Top Women in Biotech, FierceMedicalDevice’s Top Women in Medtech, and Silicon Valley Business Journal’s 100 Women of Influence. She holds B.S., M.S. and Ph.D. degrees from Georgia Tech.

John Graham

John Graham

Vice President and Head of Value Evidence and Outcomes

John Graham leads the Value Evidence and Outcomes (VEO) organization within GlaxoSmithKline’s R&D division. The VEO organization is accountable for the evidence generation strategy and implementation as well as providing strategic input into the progression of assets. The VEO organization leads the strategy behind all Real-World Evidence within GSK.

Mr Graham moved to GSK in June of 2014 to lead the CV,Met,Ren,NS and Rare Disease VEO teams and in November 2015 was appointed as Head for the entire VEO organization. He holds a Doctorate of Pharmacy degree from Idaho State University as well as a Residency Certificate from the University of Nebraska Medical Center. He has published multiple articles across various TAs. Previously Mr Graham worked for 16 years at Bristol-Myers Squibb with positions across both US and Global Medical eventually leading the US HEOR function.

Annie Lamont

Annie Lamont

Managing Partner

Annie Lamont is a Managing Partner of Oak HC/FT where she focuses on growth equity and early-stage venture opportunities in healthcare information services and financial services technology. She also serves as a Managing Partner of Oak Investment Partners. Ms Lamont has been ranked as the top healthcare and fintech investor on the Forbes Midas List.

She currently serves on the Boards of Acculynk, Aspire Health, Benefitfocus, Candescent Health, Castlight Health, Freshbooks, Hometeam, Independent Living Systems, Poynt, Precision for Medicine Holdings, Quartet Health, VillageMD and xG Health Solutions. Prior investments include athenahealth, American Esoteric Laboratories (acquired by Sonic Healthcare Limited), Argus Information & Advisory Services (acquired by Verisk Analytics), CareMedic Systems (acquired by Ingenix), CLARiENT (acquired by GE Healthcare), Harbor Payments (acquired by American Express), Health Dialog (acquired by British United Provident Association), Odyssey Healthcare, Oak Tree/Oxford, NetSpend (acquired TSYS), PayFlex Systems (acquired by Aetna), PharMEDium Healthcare (acquired by CD&R), Point Carbon (acquired by Thomson Reuters), Psychiatric Solutions, TxVia (acquired by Google) and United BioSource (acquired by Medco Health Solutions).

Ms Lamont also serves on the board of HCA Holdings and is a member of The Advisory Council for the Financial Solutions Lab (CFSI and JP Morgan Chase). She served on the Stanford University Board of Trustees, and on the Executive Board of the National Venture Capital Association.

She graduated from Stanford University with a BA in Political Science.

Woody Scal

Woody Scal

Chief Business Officer

Woody Scal has been Fitbit’s Chief Business Officer since October 2010. From 2007-2010, he served as a partner at Avanti Growth Partners, a private equity and consulting firm. Prior to Avanti, Mr Scal served as Executive Vice President and a member on the board of directors at CamelBak Products and Senior Vice President at Kransco Partners (a private equity firm). Before that he was Director of Business Development at Kransco Group Companies (a toy company), Director of Development at Visa International, Product Manager at General Mills, and an analyst at Cambridge Associates. He holds a BA in History from Williams College and an MBA from Stanford Business School.

Jonathan Linkous

Jonathan Linkous

American Telemedicine Association

Jonathan D. Linkous is the Chief Executive Officer of the American Telemedicine Association (ATA), based in Washington, DC.  As the chief staff executive of ATA since its inception in 1993, Mr Linkous has lectured and written extensively in the U.S. and other countries on healthcare modernization and related technology issues, emerging applications and market trends.  He has served on a variety of national and international advisory bodies including the FCC Hurricane Katrina Advisory Panel, the HHS Chronic Care Workgroup and the joint FCC-NTIA Advisory Committee on Communications Capabilities of Emergency Medical and Public Health Care Facilities.

Mr Linkous has 30 years’ experience in public policy related to healthcare, telecommunications and aging in both the corporate and public sectors.  In the private sector he has provided consulting services to many of the nation’s leading telecommunications, technology and healthcare companies.  Previously, he served as a national leader in aging services as the Executive Director of the National Association of Area Agencies on Aging and was as a senior executive with the National Association of Regional Councils and the Appalachian Regional Commission.

Mr Linkous holds a Masters Degree in Public Administration from the School of Government and Public Affairs at the American University in Washington, D.C. and a Degree in Business Administration from Franklin University in Columbus, Ohio with additional postgraduate work at the LBJ School of Public Affairs in Austin, Texas.

Talya Miron-Shatz

Talya Miron-Shatz

CEO and Founder

Talya Miron-Shatz specializes in medical decision making. Her research, published in fifty scientific papers and counting, examines patient and physician behavior. She applies her insights widely in the health industry and her core areas of focus are adherence to medication, and developing scientifically valid interventions for improving adherence through behavioral means. Dr Miron-Shatz also examined digital means of promoting adherence, often combining them with scalable offline support for older patients.

Another area of focus is patient engagement, starting at the most basic levels of comprehension, and moving on to ongoing patient engagement. She also studies prescriber behavior in a new focus, examining what happens when a status-quo drug is challenges, and how compensation policy affects drug choice.

A PhD in psychology, Dr Miron-Shatz was the post-doctoral fellow of Nobel Laureate Daniel Kahneman at Princeton University. She taught consumer behavior at Wharton, University of Pennsylvania, with an emphasis on health consumerism. She is a senior fellow at NYC’s Center for Medicine in the Public Interest, and a professor at the Ono Academic College.

In terms of industry involvement, Dr Miron-Shatz is CEO of CureMyWay, a leading health consultancy. Among her clients were InTouch Solutions, Edelman PR, DraftFCB, Novartis, BMS, JNJ, Pfizer, Abbvie, Samsung, NantMobile and numerous startups. She ran the Pharma 2.0 series for NYC’s Health 2.0 Meetup, and runs the eHealth Venture Summit and Innovation Award annually at MEDICA.

Her start-up company, Buddy&Soul, now part of IBM’s Alpha Zone Accelerator, is creating unique and a comprehensive solution for personal development and ongoing patient engagement.

Dave Schulte

Dave Schulte

Managing Director
McKesson Ventures

Dave Schulte is a Managing Director at McKesson Ventures.  For more than 18 years, as an investor and investment banker, he has been partnering with entrepreneurs to grow innovative healthcare and technology businesses.

Prior to McKesson Ventures, he helped build Kaiser Permanente Ventures from $20M to $400M of assets under management.  He led an investment team, who’s health technology investments included: Omada Health, Proteus Digital Health, Health Catalyst, KitCheck, Validic, Ingenious Med and MetricStream.

Prior to KP Ventures, Mr Schulte was a software and healthcare investment banker at J.P. Morgan (Hambrecht & Quist), UBS, and Piper Jaffray. He is a graduate of St. John’s University and earned a Master of Public Policy degree from Harvard University.

Olivier Hua

Olivier Hua

CEO, Bewell Connect
General Manager, Visiomed Group

Olivier Hua is General Manager of Visiomed Group and CEO of Bewell Connect Corp, its US subsidiary, based in Boston. Visiomed Group is a French company listed in Paris which has developed under the BewellConnect brand a full range of medical devices connected to one single app. This app is a personal health assistant that includes artificial intelligence to do a first triage prior to allow its user to connect virtually to a real doctor. Mr Hua has been with the company since 2009 initially as a director and as a manager since beginning 2015.

Prior to his current position, he has been for 14 years a venture investor, in France, in tech companies. Among others he has been an early investor in Vistaprint and Photobox which both became worldwide leaders in their respective fields. From 1981 to 1999, Mr Hua was a successful banker in Paris and London, and managed small industrial companies in the automotive field.

Michael  Mittelman

Michael Mittelman

Vice President Strategic Partnerships and Patient Advocacy
American Living Organ Donor Fund

Michael Mittelman is currently the Co-founder and Vice President of Patient Advocacy and Partnerships of the American Living Organ Donor Fund, a patient rights group focused on helping living organ donors in their quest to become a donor. Michael also works as a Product Development Manager at Independence Blue Cross. He is a former Patient Editor at The BMJ and former CEO and Co-founder of PHmHealth, a digital health company focused on post-acute care and compliance. His experience as a patient spans over 3 decades. He is a 3-time kidney transplant recipient with other chronic conditions. Michael was invited to testify/advocate before the FDA and serves as PCORI (Patient-Centered Outcomes Research Institute) patient representative. Additionally, he serves on the steering committee of a PCORI-Funded initiative. He has also overseen the mobile app development taskforce and the data governance taskforce for the same PCORI-funded initiative, the NephCure Kidney Network. Michael is a tireless, independent patient advocate and a healthcare strategist. He strongly believes that patients should play integral roles in healthcare companies and government agencies. 

Michael holds an MBA in Healthcare Management from the Fox School of Business at Temple University.  He also has a BA in Biological Basis of Behavior from the University of Pennsylvania. He is a published author, recent pieces in the American Journal of Transplantation and the BMJ.

Omri Shor

Omri Shor

CEO and Co-founder

Omri Shor is the CEO & Co-founder of Medisafe. He was inspired to create MediSafe with his brother after their diabetic father accidentally double-dosed on insulin. Tapping into his considerable entrepreneurship experience, he successfully delivered the product to market in less than a year.

Previously, Mr Shor served as a VIce President of Marketing & Product for ‘legal app’ developer, Masadit Software, where he increased the company’s roster from 8 to 2,000 clients, enabling it to reach sustainable profitability. Prior to that, he founded, planned to be the “Airbnb" of Marinas and Yachts. In addition, he managed a department of twenty-five salespeople for Yedioth Ahronot, Israel’s most widely circulated newspaper. Mr Shor received an MBA in Entrepreneurship & Strategy, cum laude, from The College of Management - Academic Studies (COMAS) in Rishon Le-Zion, Israel. He lives in Boston, MA with his wife and 2 children.

Quinn Solomon

Quinn Solomon

Principal and Digital Health Leader
Deloitte Digital

Quinn Solomon is a Principal at Deloitte and is the Digital Health Leader within Deloitte Digital. With over 15 years of experience working in the Plan and Provider sectors, he has helped leading health care organizations to improve patient safety, deploy consumer-facing technologies across web and mobile platforms, and address significant cost challenges through the adoption of cloud-based technologies. He focuses at the intersection of digital technologies with our healthcare system to improve outcomes, enhance patient and member experiences to increase loyalty, and leverage advanced technology to reduce costs.

Mr Solomon leads Deloitte’s investments in pre-built digital solutions and accelerators for Health Plan and Provider clients, including mobile and platform based solutions. He is responsible for Deloitte’s go to market relationship with multiple vendors in the Plans and Provider sectors.

Rob Rebak

Rob Rebak


Rob Rebak is the CEO of AbilTo. A 25-year health industry veteran, he most recently served as President, Consumer Solutions for Sharecare, a health and wellness patient engagement platform. He joined Sharecare through its acquisition of QualityHealth, a patient acquisition platform, where he was Chairman and Chief Executive Officer. Mr Rebak also previously served as Chief Executive Officer of ParentingTeensNetwork and as Managing Partner of Rosetta, which was later acquired by Publicis. He joined Rosetta through its acquisition of SimStar, where he served as President. Earlier in his career, he spent 10 years in a range of commercial roles at Pfizer, Merck, and Bristol-Myers Squibb.

Mr Rebak holds an MBA in Finance and Marketing from the University of Chicago Booth School of Business and a BA in History and Economics from Vanderbilt University.

David Martin

David Martin

Global Digital Innovation Leader

David Martin is Deloitte Consulting's Global Digital Innovation Leader.  Until recently, he served as the Global Strategy leader and led the Monitor Deloitte business in China.

He has extensive experience with numerous healthcare companies developing next generation business models based on patient needs. He has studied ecosystems in multiple countries to identify how buying behavior, payment modes, pricing, market growth and access, demand for evidence, and other drivers are shaping the need for entirely new strategies. He has also worked extensively to understand and capitalize on healthcare disruptions.  From strategy to execution, he has worked with executives to re shape their portfolios and commercial organizations to deliver breakthrough growth.

Mr Martin has written and spoken extensively on the topics of healthcare and the global growth.  Over the last few years he has spoken at the Deutsche Bank Global Healthcare Conference and the Global Business Coalition Annual Conference.  In China he was the keynote speaker for Clinical Trials 7 and the OrbiMed innovation conference.

Brett Davis

Brett Davis

General Manager, ConvergeHEALTH

Brett Davis is the General Manager of ConvergeHEALTH and a principal with Deloitte Consulting. In addition to his role at ConvergeHEALTH, he serves on the board of directors of the tranSMART Foundation, and the external advisory boards of both the University of Pennsylvania’s Center for Medical Ethics and Health Policy and the Jefferson School of Population Health. He was also a board member of the Personalized Medicine Coalition for six years. Prior to joining ConvergeHEALTH, Mr Davis was the Senior Director for global business development and strategy at Oracle Health Sciences, and a business unit executive in IBM’s healthcare and life sciences business. He is a graduate of The Pennsylvania State University.

André  Larente

André Larente


André Larente has been active in the information technology sector for more than 26 years. He has previously held leading management positions with companies such as Siemens, Syscan International, Newbridge Networks, Legent Corporation, Cognos, Tandem Computers and Honeywell Information Systems. His extensive business contacts and experience in the information technology sector, have enabled him to position DIAGNOS for rapid growth.

Michael  Rea

Michael Rea

Founder and CEO
Rx Savings Solutions

Michael Rea founded Rx Savings Solutions in 2008 after routinely witnessing consumers struggling to pay for their medications. He noticed quickly at that time that consumers were paying much more than they needed to, which was attributable to a lack of information available to them. He set out on his mission to arm consumers with this information and add efficiency and transparency back into the world of pharmacy. Dr Rea has been involved with research surrounding pharmacy transparency for over 10 years. He received his Doctor of Pharmacy degree from Creighton University.


FT Moderators (2)

David  Crow

David Crow

Senior US Business Correspondent
Financial Times

David Crow is a Senior US Business Correspondent for the Financial Times, covering telecoms, technology, and pharmaceuticals. He is based in New York. He previously worked on the FT's main news desk in London, where he edited the front page of the print edition. Before joining the FT he was Managing Editor of City AM, the London financial newspaper.

Mr Crow has an MA in English Literature from the University of Glasgow.

Aimee Keane

Aimee Keane

Reporter and Multimedia Journalist
Financial Times

Aimee Keane is a reporter and multimedia journalist for the Financial Times based in New York. She joined the FT in 2015, and has reported on the healthcare and leisure sectors. She also produces the FT's weekly business and economist podcast, Alphachat.

Ms Keane has an MS in Journalism from Northwestern University.

Agenda - 27th Oct

  • 8:00am
    Registration and breakfast
  • 9:00am
    Welcome remarks from the chair

    David Crow, Senior US Business Correspondent, Financial Times

  • 9:05am
    Opening keynote address

    How can we achieve a digitized healthcare system that allows for industry-wide collaboration between all stakeholders and greater empowerment of patients? This session will commence with a keynote address followed by a fireside chat

    Ryan Olohan, Head of Healthcare, Google

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 9:35am
    Panel: Adopting digital health – what needs to be done?

    The potential of digital health is undeniable; proactive healthcare, reduced primary care costs, patient empowerment and consumer well-being. However, making sure healthcare’s digital transformation is widely available and cost effective for all stakeholders still poses some major challenges. Interoperability for one is an obstacle that threatens the development of digital healthcare as traditionally its systems are unable to integrate with new technologies. How can this industry-wide problem be overcome? A leading panel discusses how an industry traditionally known for being slow at transformation can make the leap and adapt to the new digital era.

    Tom Beauregard, Executive Vice President and Chief Innovation Officer, UnitedHealth Group

    Rob Rebak, CEO, AbilTo

    Woody Scal, Chief Business Officer, Fitbit

    Quinn Solomon, Principal and Digital Health Leader, Deloitte Digital

    Moderator: Aimee Keane, Reporter and Multimedia Journalist, Financial Times

  • 10:20am
    Interview: The rise of the digital doctor and its role in primary care

    The landscape for doctors and patients is changing. Where once patients had very limited access to condition and treatment information, connected and mobile technology now allow patients to be proactive and take greater control of their diagnosis, treatment and aftercare. On the flip side doctors also have access to a much wider range of data, data that is available at the click of a button and which allows doctors to become more efficient with their time and treatment. 

    Dr Steven Corwin, President and CEO, NewYork-Presbyterian Hospital

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 10:35am
    Networking break
  • 11:05am
    Panel: Creating efficient digital pathways for patients and their data

    Healthcare systems such as Accountable Care Organizations, have the power to be incredibly strong and resourceful research engines. Their assets – doctors, clinics, labs and hospitals to name a few – acquire vast amounts of data on a daily basis. Harnessed in conjunction with each other, these data sets could be a driving force behind more sustainable and cost-effective primary care, whilst also harnessing the power of new digital devices. Using data sets in isolation will not solve the problem so how can digital technologies and data be used in such a way to ensure every patient is a research patient?

    Olivier Hua, CEO, Bewell Connect; General Manager, Visiomed Group

    Deborah Kilpatrick, CEO, Evidation Health

    Jonathan Linkous, CEO, American Telemedicine Association

    Talya Miron-Shatz, CEO and Founder, CureMyWay

    Moderator: Brett Davis, General Manager, ConvergeHEALTH, Deloitte

  • 11:50am
    In conversation with the FT: Power and privacy – the importance of cyber security in digital health

    Bakul Patel, Associate Director for Digital Health, US Food and Drug Administration talks to the FT and discusses the latest developments and threats surrounding patient protection in the healthcare industry and how all stakeholders will need to address cyber security in order to protect medical data

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 12:10pm
    Panel: Financing digital health – how long can the funding boom last?

    The digital health industry is still relatively new and in the past four years has seen its venture funding levels dramatically increase, almost fourfold over the period. However, whilst the R&D and potential behind digital health is still hyped about, companies are desperately trying to prove they can make money. Recent examples of companies who have had IPOs have seen mixed results and in some cases have seen their share price significantly drop. A panel of healthcare finance experts analyse the future of digital health funding.

    • Is there a sense of finance reality coming back into the market?
    • Are all digital health companies going to experience a restriction on funds, not just ones that are being publicly listed?
    • Assessing the balance of healthcare investors and technology investors in the industry and which should digital health companies look to attract?

    Esther Dyson, Executive Founder, Way to Wellville and Chairman, EDventure

    Jody Holtzman, Senior Vice President, Enterprise Strategy and Innovation, AARP

    Annie Lamont, Managing Partner, Oak HC/FT

    Dave Schulte, Managing Director, McKesson Ventures

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 12:50pm
    Keynote fireside chat

    Dr Amrit Ray, Chief Medical Officer, Janssen Pharmaceuticals

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 1:10pm
  • 2:15pm
    Panel: Creating simple and effective payments for digital health

    A lack of defined reimbursement models as well as knowledge about the exact costings of medicine and medical devices is a common problem within healthcare. With regards to reimbursement, mHealth (health-related apps and wearable devices) in particular is causing concern because it is growing rapidly in demand and is difficult to monetize as reimbursement methods are so blurred. In terms of drug costs, then greater transparency is required in order for consumers to better understand their justification of payment. So can the industry get reimbursed effectively? What forms of evidence should be used in order to justify digital health payment and what opportunities are there for technology to be used to help consumers and patients save money on their healthcare?

    Dr Michael Rea, Founder and CEO, Rx Savings Solutions

    Moderator: Aimee Keane, Reporter and Multimedia Journalist, Financial Times

  • 2:45pm
    Spotlight session: The start-up disruptors

    Small scale disruptors have dominated the backbone of digital health innovation since the industry’s inception. They range significantly in terms of application, purpose and delivery however they have all played a vital role in attempting to bring disruption back to the patient through proactive healthcare technologies. Three 15-minutes interviews, each commencing with a 5-minute opening presentation will showcase the latest innovations within the industry.

    2:45pm     Dr Jean Nehme, CEO, Touch Surgery

    3:00pm     Artem Petakov, President and Co-founder, Noom

    3:15pm     Omri Shor, CEO and Co-founder, Medisafe

    3:30pm     André Larente, President, DIAGNOS

    Moderator: David Martin, Global Digital Innovation Leader, Deloitte Consulting

  • 3:45pm
    Pre-panel keynote - The pharma perspective

    Professor Yitzhak Peterburg, Chairman of the Board of Directors, Teva Pharmaceutical Industries 

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 3:55pm
    Panel: The pharma perspective

    With governments trying to cut healthcare costs around the world, finding new products, drugs and devices is getting harder. With the rise of digital health – and specifically an enormous increase in the amount of available data sets – pharma companies are set to potentially lose more control over their future business. However sharing more data and collaborating more with the biotech and tech industries could allow them to become more outcome focused rather than asset controlling. An industry leading panel discusses how a future pharmaceutical company needs to act in order to maintain their foothold in an evolving healthcare industry.

    John Graham, Vice President and Head of Value Evidence and Outcomes, GSK

    Professor Yitzhak Peterburg, Chairman of the Board of Directors, Teva Pharmaceutical Industries

    Judy Sewards, Vice President, Head of Digital Strategy & Data Innovation, Pfizer

    Dr Susan Shiff, Senior Vice President, Center for Observational and Real-World Evidence, Merck

    Moderator: David Crow, Senior US Business Correspondent, Financial Times

  • 4:45pm
    In conversation with the patient

    Michael Mittelman, Patient Advocate; CEO, PHmHealth

    Moderator: Aimee Keane, Reporter and Multimedia Journalist, Financial Times

  • 5:05pm
    Closing remarks from the Chair

    David Crow, Senior US Business Correspondent, Financial Times

Who Attends?

CEOs, Chief Medical Officers, CFOs, CTOs, CIOs, Heads of Healthcare, Directors of Innovation, Managing Directors, Healthcare Investment, Technology Directors, Heads of Life Sciences, Heads of Disruptive Innovation, Heads of R&D and other senior executives from the following companies:

  • Life science companies 
  • Pharmaceutical and biotechnology companies 
  • Healthcare providers 
  • Multi-technology corporations 
  • Investment banks 
  • Medical device manufacturers 
  • Health insurers 
  • Health/big data companies 
  • Multi-technology corporations 
  • Venture capitalists 
  • Health regulatory agencies 
  • Mobile app providers 
  • Mobile operators and service providers 
  • Technology consultancies 
  • Management consultancies 
  • Telemedicine companies 
  • Mobile technology manufacturers 
  • Digital health companies 
  • Data integrators/analytics/brokers 
  • Genomics/personalised medicine related companies 
  • Wireless-device manufacturers

Why Attend?

  • Assess how health technologies can give greater control to patients via more proactive health and wellness management
  • Trulyidentify the ways in which digital health can be fully adopted and not just hyped about
  • Gain insight into how far the funding boom for digital health is willing to go before wide-scale commercial viability is achieved
  • Validate the threat of cyber attacks in healthcare as more and more technologies and data systems are incorporated into the industry
  • Meet and hear from leading pharmaceutical executives on how their stance on digital health is changing in light of boundaries lines in healthcare becoming more blurred

Why Sponsor?

  • Gain access to senior decision makers across the full spectrum of the healthcare industry
  • Brand alignment with the FT and its unrivalled credibility
  • Demonstrate thought leadership around the current critical issues affecting the healthcare sector
  • Benefit from sustained international visibility through our advertising and marketing campaigns


Convene - 237 Park Avenue
237 Park Avenue
New York 10017

United States of America

Tel: +1 (646) 661-7163



For accommodation options near to the venue, please click here.


With the Support of (1)

About Life Sciences and Health Care at Deloitte*

Deloitte’s life sciences and health care (LSHC) industry group is composed of over 12,000 professionals in over 90 countries. These professionals understand the complexity of today’s life sciences and health care industry challenges, and provide clients with integrated, comprehensive services that meet their respective needs. In today’s environment, LSHC professionals from across the Deloitte network help companies to evolve in a changing marketplace, pursue new and innovative solutions, and sustain long-term profitability.

For more information, visit or email

*Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited (DTTL), a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity.

Lead Sponsors (3)

AARP is the nation’s largest nonprofit, nonpartisan organization dedicated to empowering Americans 50 and older to choose how they live as they age. With nearly 38 million members and offices in every state, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, AARP works to strengthen communities and advocate for what matters most to families with a focus on health security, financial stability and personal fulfillment. AARP also works for individuals in the marketplace by sparking new solutions and allowing carefully chosen, high-quality products and services to carry the AARP name. As a trusted source for news and information, AARP produces the world’s largest circulation publications, AARP The Magazine and AARP Bulletin. To learn more, visit or follow @AARP and @AARPadvocates on social media.

Diabetes is a global problem faced simultaneously by individuals, healthcare providers, and governments. Most countries and most citizens are not taking advantage of sight-preserving screening which is easily accomplished by a simple set of photographs of the back of the eye.

Diagnos Inc. is a leader in diabetic retinopathy screening and healthcare technical services including algorithm development, data analysis, and image processing.
Diagnos is a Canadian corporation publicly traded on the Toronto Stock Exchange under the symbol ADK (TSX Venture: ADK). We employ experts in the fields of natural resources and healthcare supporting our two business units, and various scientists and technical experts with advanced academic degrees.
We develop solutions for two distinct markets. 
DIAGNOS extends the field of data mining beyond known applications.

UnitedHealth Group (NYSE: UNH) is a diversified health and well-being company dedicated to helping people live healthier lives and making health care work better. UnitedHealth Group offers a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services. For more information, visit UnitedHealth Group at or follow @UnitedHealthGrp on Twitter.

Supporting partners (4)

GBCHealth is a coalition of companies and organizations committed to investing their resources to make a healthier world… for their employees, for the communities in which they work and for the world at large.  

Since 2001 GBCHealth has helped hundreds of companies develop and implement their own global health programs, brokered countless global and local public-private partnerships and connections and effectively leveraged business advocacy in service of public health. Through convening’s, partnership creation, advocacy and thought leadership, innovative financing and spearheading carefully selected initiatives, GBCHealth is the advisor of choice for companies interested in bringing their assets, skills and passion to help meet our shared goals for health.

HCPEA is a not-for-profit trade association whose mission is to support the reputation, knowledge, and relationships of the healthcare private equity community.

As the first sector-focused trade association in private equity, HCPEA's 50+ member firms are among the the best known, most respected private equity firms located throughout the United States and Canada. The Association strives to promote a greater understanding of private equity's contribution to the healthcare economy by supporting initiatives that make healthcare an appealing sector for investment, promoting institutional/limited partner investment within the sector, investing in the professional development of our members, and facilitating collaboration between our members and the larger healthcare community.

The New York eHealth Collaborative (NYeC) is a not-for-profit organization, working in partnership with the New York State Department of Health to improve healthcare for all New Yorkers through health information technology (health IT).

Founded in 2006 by healthcare leaders, NYeC receives funding from state and federal grants to serve as the focal point for health IT in the State of New York. NYeC develops policies and standards, assists healthcare providers in making the shift to electronic health records, and coordinates the creation of the Statewide Health Information Network of New York (SHIN-NY), a network to connect healthcare providers statewide.’s detailed country-specific reports - Healthcare and Life Sciences Review - deliver up an engaging mix of insight, opinion and market intelligence straight from the corporate boardrooms of some of the world’s most high performance economies.

Download our latest country report on 





Contact Us

Chandni Saberwal
Marketing, Media Partner & Press Inquiries
Financial Times
Funmbi Adenubi
Delegate Booking and Registration Enquiries
Financial Times
Charlie Hayward
Speaking Opportunities
Financial Times
Tim Powell
Sponsorship Opportunities
Financial Times